Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma

G. Sobel, Júlia Németh, András Kiss, G. Lotz, I. Szabó, N. Udvarhelyi, Z. Schaff, C. Páska

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective.: The expression of claudins, the main tight junction proteins involved in cell adhesion and carcinogenesis, was studied in endometrioid (type I) and seropapillary (type II) endometrial adenocarcinoma. The characteristics and possible diagnostic potential of claudin expression pattern were investigated in the two cancer types having different prognosis. Methods.: Protein and mRNA expression of claudins was evaluated in 17 endometrioid carcinomas and 15 seropapillary adenocarcinomas by immunohistochemistry and real-time PCR in comparison with 38 cases of hyperplasia, normal proliferative and secretory endometrium samples. Further, protein expressions used in diagnostics (estrogen and progesterone receptors, p53, PCNA and β-catenin) were also studied. Results.: In endometrioid carcinoma and hyperplasia low claudin 1 and high claudin 2 protein contents, whereas in seropapillary adenocarcinoma high claudin 1 and low claudin 2 levels were detected. Intense protein expression was noted for claudins 3, 4, 5, and 7, without significantly different patterns in carcinoma, hyperplasia, secretory, and proliferative endometrium. Real-time PCR results confirmed differences in claudin 1 but not claudin 2 mRNA expression, whereas some minor discrepancies were observed in comparison with immunohistochemistry patterns. Conclusion.: The two types of endometrial adenocarcinomas were well distinguished by claudins 1 and 2 by immunohistochemistry, claudins 3, 4, and 7, however, did not prove useful in distinguishing the two entities. The similar claudin pattern seen in hyperplasia and endometrioid carcinoma and the differences regarding seropapillary adenocarcinoma support the dualistic model of endometrial carcinogenesis. The claudin pattern of the two tumor types might reflect a different cellular or pathogenetic pathway as well as a different cell adhesion behavior explaining the invasive properties.

Original languageEnglish
Pages (from-to)591-598
Number of pages8
JournalGynecologic Oncology
Volume103
Issue number2
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Claudins
Claudin-1
Papillary Adenocarcinoma
Adenocarcinoma
Endometrioid Carcinoma
Hyperplasia
Claudin-2
Immunohistochemistry
Endometrium
Cell Adhesion
Real-Time Polymerase Chain Reaction
Carcinogenesis
Tight Junction Proteins
Catenins
Proteins
Proliferating Cell Nuclear Antigen
Progesterone Receptors
Estrogen Receptors
Neoplasms
Carcinoma

Keywords

  • Claudins
  • Endometrioid carcinoma
  • Seropapillary endometrial adenocarcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. / Sobel, G.; Németh, Júlia; Kiss, András; Lotz, G.; Szabó, I.; Udvarhelyi, N.; Schaff, Z.; Páska, C.

In: Gynecologic Oncology, Vol. 103, No. 2, 11.2006, p. 591-598.

Research output: Contribution to journalArticle

@article{87659f2e67da49edb5933c5c6fd269fa,
title = "Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma",
abstract = "Objective.: The expression of claudins, the main tight junction proteins involved in cell adhesion and carcinogenesis, was studied in endometrioid (type I) and seropapillary (type II) endometrial adenocarcinoma. The characteristics and possible diagnostic potential of claudin expression pattern were investigated in the two cancer types having different prognosis. Methods.: Protein and mRNA expression of claudins was evaluated in 17 endometrioid carcinomas and 15 seropapillary adenocarcinomas by immunohistochemistry and real-time PCR in comparison with 38 cases of hyperplasia, normal proliferative and secretory endometrium samples. Further, protein expressions used in diagnostics (estrogen and progesterone receptors, p53, PCNA and β-catenin) were also studied. Results.: In endometrioid carcinoma and hyperplasia low claudin 1 and high claudin 2 protein contents, whereas in seropapillary adenocarcinoma high claudin 1 and low claudin 2 levels were detected. Intense protein expression was noted for claudins 3, 4, 5, and 7, without significantly different patterns in carcinoma, hyperplasia, secretory, and proliferative endometrium. Real-time PCR results confirmed differences in claudin 1 but not claudin 2 mRNA expression, whereas some minor discrepancies were observed in comparison with immunohistochemistry patterns. Conclusion.: The two types of endometrial adenocarcinomas were well distinguished by claudins 1 and 2 by immunohistochemistry, claudins 3, 4, and 7, however, did not prove useful in distinguishing the two entities. The similar claudin pattern seen in hyperplasia and endometrioid carcinoma and the differences regarding seropapillary adenocarcinoma support the dualistic model of endometrial carcinogenesis. The claudin pattern of the two tumor types might reflect a different cellular or pathogenetic pathway as well as a different cell adhesion behavior explaining the invasive properties.",
keywords = "Claudins, Endometrioid carcinoma, Seropapillary endometrial adenocarcinoma",
author = "G. Sobel and J{\'u}lia N{\'e}meth and Andr{\'a}s Kiss and G. Lotz and I. Szab{\'o} and N. Udvarhelyi and Z. Schaff and C. P{\'a}ska",
year = "2006",
month = "11",
doi = "10.1016/j.ygyno.2006.04.005",
language = "English",
volume = "103",
pages = "591--598",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma

AU - Sobel, G.

AU - Németh, Júlia

AU - Kiss, András

AU - Lotz, G.

AU - Szabó, I.

AU - Udvarhelyi, N.

AU - Schaff, Z.

AU - Páska, C.

PY - 2006/11

Y1 - 2006/11

N2 - Objective.: The expression of claudins, the main tight junction proteins involved in cell adhesion and carcinogenesis, was studied in endometrioid (type I) and seropapillary (type II) endometrial adenocarcinoma. The characteristics and possible diagnostic potential of claudin expression pattern were investigated in the two cancer types having different prognosis. Methods.: Protein and mRNA expression of claudins was evaluated in 17 endometrioid carcinomas and 15 seropapillary adenocarcinomas by immunohistochemistry and real-time PCR in comparison with 38 cases of hyperplasia, normal proliferative and secretory endometrium samples. Further, protein expressions used in diagnostics (estrogen and progesterone receptors, p53, PCNA and β-catenin) were also studied. Results.: In endometrioid carcinoma and hyperplasia low claudin 1 and high claudin 2 protein contents, whereas in seropapillary adenocarcinoma high claudin 1 and low claudin 2 levels were detected. Intense protein expression was noted for claudins 3, 4, 5, and 7, without significantly different patterns in carcinoma, hyperplasia, secretory, and proliferative endometrium. Real-time PCR results confirmed differences in claudin 1 but not claudin 2 mRNA expression, whereas some minor discrepancies were observed in comparison with immunohistochemistry patterns. Conclusion.: The two types of endometrial adenocarcinomas were well distinguished by claudins 1 and 2 by immunohistochemistry, claudins 3, 4, and 7, however, did not prove useful in distinguishing the two entities. The similar claudin pattern seen in hyperplasia and endometrioid carcinoma and the differences regarding seropapillary adenocarcinoma support the dualistic model of endometrial carcinogenesis. The claudin pattern of the two tumor types might reflect a different cellular or pathogenetic pathway as well as a different cell adhesion behavior explaining the invasive properties.

AB - Objective.: The expression of claudins, the main tight junction proteins involved in cell adhesion and carcinogenesis, was studied in endometrioid (type I) and seropapillary (type II) endometrial adenocarcinoma. The characteristics and possible diagnostic potential of claudin expression pattern were investigated in the two cancer types having different prognosis. Methods.: Protein and mRNA expression of claudins was evaluated in 17 endometrioid carcinomas and 15 seropapillary adenocarcinomas by immunohistochemistry and real-time PCR in comparison with 38 cases of hyperplasia, normal proliferative and secretory endometrium samples. Further, protein expressions used in diagnostics (estrogen and progesterone receptors, p53, PCNA and β-catenin) were also studied. Results.: In endometrioid carcinoma and hyperplasia low claudin 1 and high claudin 2 protein contents, whereas in seropapillary adenocarcinoma high claudin 1 and low claudin 2 levels were detected. Intense protein expression was noted for claudins 3, 4, 5, and 7, without significantly different patterns in carcinoma, hyperplasia, secretory, and proliferative endometrium. Real-time PCR results confirmed differences in claudin 1 but not claudin 2 mRNA expression, whereas some minor discrepancies were observed in comparison with immunohistochemistry patterns. Conclusion.: The two types of endometrial adenocarcinomas were well distinguished by claudins 1 and 2 by immunohistochemistry, claudins 3, 4, and 7, however, did not prove useful in distinguishing the two entities. The similar claudin pattern seen in hyperplasia and endometrioid carcinoma and the differences regarding seropapillary adenocarcinoma support the dualistic model of endometrial carcinogenesis. The claudin pattern of the two tumor types might reflect a different cellular or pathogenetic pathway as well as a different cell adhesion behavior explaining the invasive properties.

KW - Claudins

KW - Endometrioid carcinoma

KW - Seropapillary endometrial adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=33750979545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750979545&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.04.005

DO - 10.1016/j.ygyno.2006.04.005

M3 - Article

VL - 103

SP - 591

EP - 598

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -